XML 25 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS SEGMENT INFORMATION
6 Months Ended
Jun. 30, 2016
Segment Reporting [Abstract]  
Business Segment Information [Text Block]
BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods.

Product revenues were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Dollars in Millions
2016
 
2015
 
2016
 
2015
Oncology
 
 
 
 
 
 
 
Empliciti (elotuzumab)
$
34

 
$

 
$
62

 
$

Erbitux* (cetuximab)

 
169

 

 
334

Opdivo (nivolumab)
840

 
122

 
1,544

 
162

Sprycel (dasatinib)
451

 
405

 
858

 
780

Yervoy (ipilimumab)
241

 
296

 
504

 
621

Cardiovascular
 
 
 
 
 
 
 
Eliquis (apixaban)
777

 
437

 
1,511

 
792

Immunoscience
 
 
 
 
 
 
 
Orencia (abatacept)
593

 
461

 
1,068

 
861

Virology
 
 
 
 
 
 
 
Baraclude (entecavir)
299

 
343

 
590

 
683

Hepatitis C Franchise
546

 
479

 
973

 
743

Reyataz (atazanavir sulfate) Franchise
247

 
303

 
468

 
597

Sustiva (efavirenz) Franchise
271

 
317

 
544

 
607

Neuroscience
 
 
 
 
 
 
 
Abilify* (aripiprazole)
35

 
107

 
68

 
661

Mature Products and All Other
537

 
724

 
1,072

 
1,363

Total Revenues
$
4,871

 
$
4,163

 
$
9,262

 
$
8,204

*
Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q.


The composition of total revenues was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Dollars in Millions
2016
 
2015
 
2016
 
2015
Net product sales
$
4,432

 
$
3,572

 
$
8,396

 
$
6,631

Alliance revenues
418

 
552

 
827

 
1,507

Other revenues
21

 
39

 
39

 
66

Total Revenues
$
4,871

 
$
4,163

 
$
9,262

 
$
8,204